Successful Enrolment Completed Across Two Cohorts

Coiled enrolled six patients in AO-252 Phase I softgel cohorts; efficacy data expected late 2026.

What the company is saying

Coiled Therapeutics plc is announcing the completion of patient enrolment in two initial dose-escalation cohorts—120mg twice-daily (BID, n=3) and 160mg once-daily (QD, n=3)—for its new lipid-based softgel formulation of AO-252, a brain-penetrant TACC3 inhibitor. The company frames this as a milestone in its ongoing Phase I trial (NCT06136884), emphasizing that all enrolled patients are progressing as planned through the protocol-specified assessment period. Management, led by CEO Sridhar Vempati, highlights the new formulation’s design goals: improved absorption consistency and bioavailability, referencing an 80% clinical benefit rate (CBR) previously observed with the earlier tablet’s twice-daily dosing (n=5), compared to 40% for once-daily dosing (n=5). The narrative stresses confidence in dosing up to 30 patients with the new formulation by year-end 2026 and advancing toward Phase I/II expansion in ovarian and prostate cancer. The announcement is optimistic in tone, focusing on operational progress and design rationale, but does not present new efficacy or safety data from the softgel formulation.

What the data suggests

The hard data confirm enrolment of six patients across two dose cohorts (120mg BID and 160mg QD, each n=3) in the Phase I trial of AO-252’s new softgel formulation. All patients are currently in the assessment period, with no safety, pharmacokinetic, or efficacy results reported for the new formulation. The only quantitative efficacy data are from the prior tablet version: 80% CBR for twice-daily dosing (n=5) and 40% CBR for once-daily dosing (n=5). The company aims to enrol up to 30 patients with the new softgel by the end of 2026, with initial safety and PK data also targeted for that timeframe. No financial figures, cash position, or operational costs are disclosed. The evidence for the new formulation’s claimed advantages remains unproven at this stage, as all supporting data are from the earlier tablet, not the softgel. The disclosure is specific on trial design and cohort progress but lacks new clinical or financial outcomes.

Analysis

The announcement is generally positive in tone, highlighting successful enrolment in two escalation cohorts and referencing encouraging historical clinical benefit rates with the prior tablet formulation. However, most of the key claims about the new softgel formulation's advantages (improved absorption, bioavailability, and predictability) are forward-looking and not yet supported by data from the current trial. The only realised progress is the enrolment of six patients and the ongoing nature of the Phase I study; all efficacy and safety outcomes for the new formulation remain unreported, with initial data not expected until the end of 2026. The company projects dosing up to 30 patients and advancing to expansion cohorts, but these are future milestones. There is no mention of large capital outlays or immediate financial impact, and no financial data is disclosed. The gap between narrative and evidence lies in the promotional framing of the new formulation's potential benefits, which are not yet substantiated by trial results.

Risk flags

• ●The main execution risk is that the new softgel formulation’s claimed improvements in absorption and bioavailability are unproven, as no clinical or pharmacokinetic data from the current trial have been disclosed; if these benefits do not materialize, the program’s differentiation may be limited.
• ●There is a risk that enrolment or data readouts could be delayed, as the company’s plan to dose up to 30 patients and report initial results by year-end 2026 leaves little margin for setbacks in recruitment, protocol adherence, or data analysis.
• ●Reliance on historical efficacy data from the prior tablet formulation (80% CBR for BID dosing, 40% for QD) to support the new softgel’s prospects may be misleading if the new formulation does not replicate or improve upon these outcomes in the current trial.

Bottom line

Coiled Therapeutics has enrolled six patients in its Phase I trial of a new AO-252 softgel, but has not yet produced any efficacy or safety data for this formulation. The company’s narrative leans heavily on historical results from the tablet version—80% CBR for twice-daily dosing and 40% for once-daily—while all claims about the softgel’s improved absorption and predictability remain untested. Investors will not see meaningful clinical data until late 2026 at the earliest, and the risk that the new formulation fails to deliver on its design promises is material. The announcement signals operational progress but does not shift the risk/reward profile until new data are reported. The key takeaway is that this is a procedural milestone, not a clinical breakthrough, and the next actionable update will be the release of safety and pharmacokinetic data from the ongoing trial.

Announcement summary

(AIM: COIL) (OTCQB: COTXF) Coiled Therapeutics plc announced the successful enrolment of patients across two escalation cohorts in the clinical development of its next-generation, lipid-based formulation of AO-252, a first-in-class, brain-penetrant small molecule inhibitor of TACC3. The two cohorts enrolled include a 120mg twice-daily (BID) group (n=3) and a 160mg once-daily (QD) group (n=3). All patients in these cohorts are progressing as planned through the protocol-specified assessment period in the ongoing Phase I study (NCT06136884). The new softgel formulation is designed to achieve more consistent, dose-proportional absorption, building on the previously observed 80% Clinical Benefit Rate (CBR) in earlier twice-daily tablet dosing (n=5), compared with a 40% CBR in once-daily tablet dosing (n=5). The company aims to dose up to 30 patients with the new formulation by the end of 2026, as the trial advances towards planned Phase I/II dose-expansion cohorts in ovarian and prostate cancer. The 120mg BID and 160mg QD dose levels were selected to optimise systemic drug exposure based on encouraging clinical activity with the original tablet formulation. The new pre-dissolved, lipid-based softgel system was specifically designed to reduce absorption variability, enhance bioavailability, and deliver more predictable, dose-proportional exposure. Enrolment across these cohorts marks continued progress towards the company's planned expansion in ovarian and prostate cancer. Initial safety and pharmacokinetic (PK) data readouts are expected by the end of 2026, in line with the company's development roadmap. Sridhar Vempati, Chief Executive Officer, stated that the new formulation was designed to enhance bioavailability and deliver more consistent drug exposure, building on the encouraging 80% clinical benefit rate signal observed with twice-daily dosing in earlier cohorts. He described this as an important step in de-risking the dose-escalation strategy and confirmed the company is on track to dose up to 30 patients by year-end. The announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law.

Disagree with this article?